Axon Enterprise (NASDAQ:AXON) Sets New 1-Year Low – Time to Sell?

Axon Enterprise, Inc (NASDAQ:AXON) shares reached a new 52-week low during trading on Tuesday . The stock traded as low as $387.80 and last traded at $391.4010, with a volume of 159891 shares changing hands. The stock had previously closed at $413.07.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Axon unveiled three AI-driven products (Axon Vision, expanded Axon Assistant, and Axon 911) designed to stitch live video, 911 data and field reporting into a single, real‑time public‑safety platform — a clear revenue/competitive narrative for investors. Axon AI tools press release
• Positive Sentiment: Multiple Wall Street analysts issued bullish notes during Axon Week (Goldman, Morgan Stanley and others), helping lift the stock as analysts emphasized AI-driven growth and reiterated buy ratings. Analyst optimism article
• Neutral Sentiment: Major firms trimmed price targets (Goldman Sachs cut $720→$625; TD Cowen cut $950→$825) but generally kept buy ratings — reduces near‑term upside expectations while still signaling conviction in the long‑term story. Price target coverage
• Negative Sentiment: Shares plunged ~10% earlier this week after a sudden selloff; coverage points to a mix of analyst target resets and new legal risks as catalysts for the drop. That volatility is still weighing on sentiment. Why shares traded lower
• Negative Sentiment: Axon hit a 52‑week low amid the pullback and broader market weakness; investors should view this as both a risk signal and a potential entry point depending on conviction in AI rollout and legal outcomes. 52-week low report
• Negative Sentiment: Ongoing legal exposure (including a HQ dispute noted in coverage) is an overhang that analysts and investors flagged as part of the recent selloff; this could create further downside risk if developments are unfavorable. Legal risk coverage
• Negative Sentiment: Macro/geopolitical jitters (U.S.–Iran tensions) and a weaker tech/open market environment amplified the move lower earlier in the week, showing the stock remains sensitive to market risk-off episodes. Market headwinds article

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Barclays dropped their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Royal Bank Of Canada decreased their target price on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 25th. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Friday, March 27th. UBS Group decreased their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Finally, Piper Sandler decreased their target price on shares of Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $755.88.

Axon Enterprise Price Performance

The firm’s 50-day moving average price is $470.33 and its 200-day moving average price is $571.34. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $31.48 billion, a PE ratio of 257.59, a PEG ratio of 8.81 and a beta of 1.61.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The business’s revenue was up 38.5% compared to the same quarter last year. During the same period in the prior year, the company earned $2.08 EPS. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Erika Nardini sold 198 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the sale, the director directly owned 1,946 shares of the company’s stock, valued at $985,804.68. This represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the completion of the sale, the chief executive officer directly owned 3,090,997 shares in the company, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 13,855 shares of company stock worth $7,109,828 over the last three months. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Axon Enterprise

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AXON. NEOS Investment Management LLC boosted its stake in Axon Enterprise by 82.7% in the third quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after acquiring an additional 11,482 shares in the last quarter. Vanguard Group Inc. boosted its stake in Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after acquiring an additional 376,904 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after acquiring an additional 5,953 shares in the last quarter. Legal & General Group Plc boosted its stake in Axon Enterprise by 3.1% in the third quarter. Legal & General Group Plc now owns 421,114 shares of the biotechnology company’s stock valued at $302,208,000 after acquiring an additional 12,736 shares in the last quarter. Finally, BIT Capital GmbH boosted its stake in Axon Enterprise by 75.6% in the third quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock valued at $2,537,000 after acquiring an additional 1,522 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.